New Hopes in Alcohol Use Disorder Treatment
Episode Overview
Varenicline and bupropion show promise in reducing alcohol consumption. Medical marijuana's role in treating anxiety is debated. RFK Jr.'s advocacy for psychedelic therapy raises both hope and concern. The study highlights the importance of biomarkers in measuring alcohol use. Side effects of medications are crucial in treatment considerations.
"Taking varenicline plus bupropion reduced alcohol consumption from 7.5 to three drinks a day on average."
Get ready to be moved by the latest episode of the Addiction Medicine Journal Club, where Dr. John Keenan and Dr. Sonya Del Tredici bring a lively discussion on cutting-edge treatments for alcohol use disorder. This time, they're tackling the combination of varenicline and bupropion, exploring their potential to reduce alcohol consumption.
With humour and a touch of scepticism, they dive into a recent study that suggests these medications might just be the new heroes in the fight against alcohol dependency. But that's not all! The duo also shares their thoughts on the controversial topic of medical marijuana for anxiety in Pennsylvania, with Dr. Keenan expressing his wish for a more honest conversation about its use.
They even throw in some thoughts on RFK Jr.'s ambitious push for psychedelic therapy, raising questions about the balance between optimism and scientific rigour. With a mix of personal anecdotes and rigorous analysis, this episode offers a fresh perspective on addiction treatment. Whether you're a medical professional or someone interested in the latest addiction research, this episode is sure to provide food for thought.
Tune in to see if these treatments could be a game-changer for those struggling with alcohol use disorder. Could this be the breakthrough you've been waiting for?